Today: 9 June 2026
Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

New York, January 22, 2026, 21:14 EST — Market closed

Booking Holdings Inc. shares edged down 0.25% to close at $5,150.90 on Thursday, capping a volatile three-day stretch for the online travel giant’s stock. The price fluctuated between $5,119.07 and $5,248.61, with roughly 220,000 shares traded.

This shift takes on extra weight with Booking’s fourth-quarter and full-year update less than a month away. Investors are sharp on any signals tied to demand, particularly business travel. Even a cautious note on bookings or margins can nudge the stock, despite the report’s operational focus.

Timing is another factor. U.S. markets reopen Friday, bringing new data on activity and confidence that could directly impact travel stocks, which often move with shifts in consumer sentiment and corporate spending.

Wall Street closed Thursday on a positive note: the Dow rose 0.63%, the S&P 500 gained 0.55%, and the Nasdaq climbed 0.91%. Against this backdrop, Booking’s slight decline seemed more an isolated blip than a sign of wider market caution.

Within the travel sector, Expedia climbed roughly 3% during the session. Tripadvisor and MakeMyTrip also saw gains, according to market data. Booking, however, slipped slightly.

On Thursday, corporate travel and expense platform Navan announced it has boosted its direct connection with Booking.com, aiming to offer more lodging options and discounts within Navan’s business travel tools. The two companies called the upgrade an enhanced “API” integration — software that enables data sharing between systems — designed to unlock more properties and rates in managed travel programs. “It’s about adding more value to every business trip,” said Navan’s Dane Molter. Booking.com’s Thibaut Leroux added the partnership broadens “business travelers’ choices.” Navan

Booking announced its calendar for the week, scheduling the release of its fourth-quarter and full-year 2025 financial results around 4:00 p.m. ET on Feb. 18. A conference call will follow at 4:30 p.m. ET. The company, a global player in online travel and related services, operates brands like Booking.com, Priceline, Agoda, KAYAK, and OpenTable.

Investors will zero in on a few clear but tough metrics in that report: growth in bookings and room nights, evidence of pricing power, and whether marketing expenses are climbing faster than revenue. If demand dips or competition drives deeper discounts, the stock usually reacts fast.

Friday’s U.S. calendar includes S&P Global’s flash manufacturing and services PMI numbers, along with the University of Michigan’s final consumer sentiment reading for January. These reports could shift rate expectations and the dollar’s direction, key factors for travel spending and multinational companies reporting in different currencies.

Still, the situation is double-edged. The Navan integration might not have an immediate impact, and corporate travel budgets can shrink quickly if executives grow wary. Plus, a stronger dollar could dampen reported growth for firms with significant overseas operations, even if actual demand stays solid.

Booking Holdings is set to report earnings on Feb. 18, after the U.S. market closes, followed by a Q&A session.

Stock Market Today

  • NOV Stock Up 32% in Six Months: Key Factors and Investor Outlook
    June 9, 2026, 10:21 AM EDT. NOV Inc. shares have surged 31.5% over six months, outpacing the Mechanical and Equipment Oil and Gas sub-industry and broader energy sector. The company benefits from strong offshore equipment demand, driven by subsea flexible pipe growth and offshore projects through 2028. NOV's focus on automation and cost reduction, including headcount and facility cuts, supports operational efficiency. Management anticipates a multi-year upcycle in capital equipment spending due to energy security and renewed offshore investment, bolstering demand. With a solid backlog and positive 2026 earnings outlook, NOV's positioning suggests potential for continued gains, raising questions for investors on whether to hold or sell amid market shifts.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Previous Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Qualcomm stock price ticks up as QCOM lines up Feb. 4 earnings — what traders watch next
Next Story

Qualcomm stock price ticks up as QCOM lines up Feb. 4 earnings — what traders watch next

Go toTop